Current Highlight from January 8, 2016
Innovation Improves Fidelity, Increases Efficiency, and Reduces Cost of Mutation Detection
Investigators combined DNA-tagging technology with highly accurate next generation sequencing to develop a novel technique that quickly and directly identifies mutations in genetically diverse pools of mutant cells. This new technology, designated by the acronym MARDI (Mutation Analysis with Random DNA Identifiers), critically reduces the cost of analysis. In addition it improves detection of mutations not observed by existing methods, and therefore can be used to confirm mutations and/or exclude false positives - both critical aspects for drug evaluation. When applied to mutant cells obtained from DMBA (7,12-dimethylbenz[a]anthracene)-treated rats and isolated by flow cytometry using the Pig-a gene mutation assay, MARDI detected nearly all mutations identified by conventional clone-by-clone analysis and discovered many additional ones, demonstrating its accuracy and sensitivity. A manuscript describing the results is available online at Environmental and Molecular Mutagenesis
.
.
For additional information, please contact Javier Revollo, Ph.D., Division of Genetic and Molecular Toxicology, FDA/NCTR.
Contact FDA
870-543-7000
National Center for Toxicological Research
Food and Drug Administration
3900 NCTR Road
Jefferson, AR 72079
.png)
No hay comentarios:
Publicar un comentario